Altimmune, Inc. 8-K

What Happened
Altimmune, Inc. (ALT) filed an 8-K on Jan 28, 2026 disclosing that on Jan 27, 2026 it entered into a Securities Purchase Agreement for a registered direct offering expected to close on or about Jan 29, 2026. The offering includes 12,397,920 shares of common stock and pre-funded warrants to purchase up to 4,647,534 additional shares. Gross proceeds are expected to be approximately $75 million before placement agent fees and expenses. Titan Partners Group LLC is acting as sole placement agent.

Key Details

• Offering size: ~12,397,920 common shares plus pre-funded warrants exercisable for up to 4,647,534 common shares.
• Expected gross proceeds: approximately $75.0 million (before fees and expenses).
• Pre-funded warrants: $0.001 exercise price, no expiration, immediately exercisable subject to a beneficial ownership limitation (default 9.99%, can be increased by holder up to 19.99% with notice and a 61‑day delay).
• Placement agent: Titan Partners; company will pay cash fees and reimburse up to $125,000 of Titan’s expenses.
• Closing: expected on or about Jan 29, 2026, pursuant to the company’s effective Form S-3 shelf registration (filed Nov 6, 2025; declared effective Dec 5, 2025).
• Lock-up: the company and its directors and executive officers agreed to 30-day lock-ups following the closing, subject to customary exceptions.
• Legal opinion and transaction documents (warrant, purchase agreement, placement agreement) were filed as exhibits to the 8-K.

Why It Matters
This transaction will raise immediate cash (~$75M) to support Altimmune’s operations or strategic priorities, but it is dilutive: new shares and exercisable pre-funded warrants will increase shares outstanding if exercised. The pre-funded warrants have a nominal exercise price and no expiration, which can accelerate dilution, although the beneficial ownership limit restricts immediate concentration by the holder. Investors should watch the final closing, exact pricing per share, and any future exercises of the pre-funded warrants for their impact on share count and per-share metrics.